American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Text Revision. Washington, DC: APA Publishing.
Barkus, EJ, Stirling, J, Hopkins, RS and Lewis, S (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39, 175–178.
Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, Martin-Santos, R, Borgwardt, S, Winton-Brown, T, Nosarti, C, O'carroll, CM, Seal, M and Allen, P (2010) Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35, 764.
Chen, C-Y, O'brien, MS and Anthony, JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug and alcohol dependence 79, 11–22.
Coffey, C, Carlin, JB, Lynskey, M, Li, N and Patton, GC (2003) Adolescent precursors of cannabis dependence: findings from the victorian adolescent health cohort study. The British Journal of Psychiatry 182, 330–336.
Curran, HV, Freeman, TP, Mokrysz, C, Lewis, DA, Morgan, CJ and Parsons, LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience 17, 293–306.
Demirakca, T, Sartorius, A, Ende, G, Meyer, N, Welzel, H, Skopp, G, Mann, K and Hermann, D (2011) Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug and Alcohol Dependence 114, 242–245.
Di Forti, M, Iyegbe, C, Sallis, H, Kolliakou, A, Falcone, MA, Paparelli, A, Sirianni, M, La Cascia, C, Stilo, SA and Marques, TR (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological Psychiatry 72, 811–816.
Di Forti, M, Sallis, H, Allegri, F, Trotta, A, Ferraro, L, Stilo, SA, Marconi, A, La Cascia, C, Reis Marques, T, Pariante, C, Dazzan, P, Mondelli, V, Paparelli, A, Kolliakou, A, Prata, D, Gaughran, F, David, AS, Morgan, C, Stahl, D, Khondoker, M, Maccabe, JH and Murray, RM (2014) Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 40, 1509–1517.
Di Forti, M, Marconi, A, Carra, E, Fraietta, S, Trotta, A, Bonomo, M, Bianconi, F, Gardner-Sood, P, O'connor, J and Russo, M (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry 2, 233–238.
D'souza, DC, Ranganathan, M, Braley, G, Gueorguieva, R, Zimolo, Z, Cooper, T, Perry, E and Krystal, J (2008) Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33, 2505–2516.
Englund, A, Morrison, PD, Nottage, J, Hague, D, Kane, F, Bonaccorso, S, Stone, JM, Reichenberg, A, Brenneisen, R and Holt, D (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. Journal of Psychopharmacology 27, 19–27.
Freeman, T and Winstock, A (2015) Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychological Medicine 45, 3181–3189.
Freeman, TP, Morgan, CJ, Hindocha, C, Schafer, G, Das, RK and Curran, HV (2014) Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 109, 1686–1694.
Freeman, TP, Van Der Pol, P, Kuijpers, W, Wisselink, J, Das, RK, Rigter, S, Van Laar, M, Griffiths, P, Swift, W and Niesink, R (2018) Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. Psychological Medicine 1–7. https://doi.org/10.1017/S0033291717003877.
Gossop, M, Darke, S, Griffiths, P, Hando, J, Powis, B, Hall, W and Strang, J (1995) The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90, 607–614.
Hasin, DS, Saha, TD, Kerridge, BT, Goldstein, RB, Chou, SP, Zhang, H, Jung, J, Pickering, RP, Ruan, WJ, Smith, SM, Huang, B and Grant, B (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 72, 1235–1242.
Hindocha, C, Shaban, ND, Freeman, TP, Das, RK, Gale, G, Schafer, G, Falconer, CJ, Morgan, CJ and Curran, HV (2015) Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom. Drug and Alcohol Dependence 148, 165–171.
Hindocha, C, Freeman, TP and Curran, HV (2017) Anatomy of a joint: comparing self-reported and actual dose of cannabis and tobacco in a joint, and how these are influenced by controlled acute administration. Cannabis and Cannabinoid Research 2, 217–223.
Hindocha, C, Norberg, MM and Tomko, RL (2018) Solving the problem of cannabis quantification. The Lancet Psychiatry 4, 643–648.
Kögel, CC, Balcells-Olivero, MM, López-Pelayo, H, Miquel, L, Teixidó, L, Colom, J, Nutt, DJ, Rehm, J and Gual, A (2017) The standard joint unit. Drug and Alcohol Dependence 176, 109–116.
Krystal, JH, Karper, LP, Seibyl, JP, Freeman, GK, Delaney, R, Bremner, JD, Heninger, GR, Bowers, MB and Charney, DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51, 199–214.
Lisdahl, KM, Sher, KJ, Conway, KP, Gonzalez, R, Feldstein Ewing, SW, Nixon, SJ, Tapert, S, Bartsch, H, Goldstein, RZ and Heitzeg, M (2018) Adolescent brain cognitive development (ABCD) study: overview of substance use assessment methods. Developmental Cognitive Neuroscience 32, 80–96.
Marconi, A, Di Forti, M, Lewis, CM, Murray, RM and Vassos, E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin 42, 1262–1269.
Martin, G, Copeland, J, Gates, P and Gilmour, S (2006) The severity of dependence scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug and Alcohol Dependence 83, 90–93.
Mason, OJ, Morgan, CJ, Stefanovic, A and Curran, HV (2008) The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophrenia Research 103, 138–142.
Mokrysz, C, Freeman, T, Korkki, S, Griffiths, K and Curran, H (2016) Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Translational Psychiatry 6, e961.
Morgan, CJ and Curran, HV (2008) Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. The British Journal of Psychiatry 192, 306–307.
Morgan, CJ, Schafer, G, Freeman, TP and Curran, HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. The British Journal of Psychiatry 197, 285–290.
Morgan, CJ, Gardener, C, Schafer, G, Swan, S, Demarchi, C, Freeman, TP, Warrington, P, Rupasinghe, I, Ramoutar, A, Tan, N, Wingham, G, Lewis, S and Curran, HV (2012) Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychological Medicine 42, 391–400.
Morgan, C, Freeman, T, Powell, J and Curran, H (2016) AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Translational Psychiatry 6, e738.
Piontek, D, Kraus, L and Klempova, D (2008) Short scales to assess cannabis-related problems: a review of psychometric properties. Substance Abuse Treatment, Prevention, and Policy 3, 25.
Potter, DJ, Hammond, K, Tuffnell, S, Walker, C and Di Forti, M (2018) Potency of Δ9–tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology. Drug Testing and Analysis 10, 628–635.
Ramaekers, JG, Kauert, G, Theunissen, EL, Toennes, SW and Moeller, MR (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. Journal of Psychopharmacology 23, 266–277.
Swift, W, Copeland, J and Hall, W (1998) Choosing a diagnostic cut-off for cannabis dependence. Addiction 93, 1681–1692.
Taylor, M, Lees, R, Henderson, G, Lingford-Hughes, A, Macleod, J, Sullivan, J and Hickman, M (2017) Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug and Alcohol Review 36, 220–226.
van der Pol, P, Liebregts, N, Brunt, T, Van Amsterdam, J, De Graaf, R, Korf, DJ, Van Den Brink, W and Van Laar, M (2014) Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109, 1101–1109.
Ventura, J, Nuechterlein, KH, Subotnik, KL, Gutkind, D and Gilbert, EA (2000) Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item brief psychiatric rating scale. Psychiatry Research 97, 129–135.
Yücel, M, Lorenzetti, V, Suo, C, Zalesky, A, Fornito, A, Takagi, MJ, Lubman, D and Solowij, N (2016) Hippocampal harms, protection and recovery following regular cannabis use. Translational Psychiatry 6, e710.